Articles related to ANTIBODY-DRUG CONJUGATES (ADCs)

Unfolding the Potentials of Anti-TROP2 ADC Therapy in Triple-Negative Breast Cancer Evolving therapeutic paradigms for triple-negative breast cancer (TNBC) are in focus, as esteemed experts highlight the use of novel anti-TROP2 antibody drug conjugates in an enlightening multidisciplinary tumor board.

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.